MeSH tree: D02.092.570.665
A randomized clinical trial found that the antidepressant fluvoxamine significantly reduces long COVID-related fatigue, one of the condition's most persistent and debilitating symptoms, while the diabetes drug metformin showed ...
Mar 31, 2026
0
6
A global research team co‑led by McMaster University has identified one of the first medications shown to meaningfully reduce fatigue in people living with long COVID—a breakthrough for millions still struggling with persistent ...
Mar 31, 2026
0
11
Since the 1980s, selective serotonin reuptake inhibitor (SSRI) antidepressants have been the backbone of treatment for depression and other mental health conditions worldwide, with tens of millions of annual prescriptions ...
May 31, 2024
0
58
A multidisciplinary research team from the LKS Faculty of Medicine (HKUMed) and the Faculty of Engineering of the University of Hong Kong (HKU) has successfully developed an innovative screening platform to rapidly assess ...
Apr 5, 2024
0
45
Researchers have developed a new method for triggering and imaging seizures in epilepsy patients, offering physicians the ability to collect real-time data to tailor epilepsy surgery. In contrast to previous practice, where ...
Mar 11, 2024
0
34
A new research article from Thomas Stewart, an associate professor of data science at the University of Virginia, examining the COVID-19 treatment fluvoxamine has been published in JAMA.
Nov 20, 2023
0
43
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking the antidepressant fluvoxamine at a dosage of 100 mg twice daily for ...
Sep 14, 2023
0
34
People who took a cheap diabetes drug after testing positive for COVID-19 had a 40 percent lower risk of getting long COVID, a US-based study said Friday.
Jun 11, 2023
0
81
For high-risk outpatients with COVID-19, treatment with oral fluvoxamine plus budesonide reduces the incidence of severe disease needing advanced care, according to a study published online April 18 in the Annals of Internal ...
Apr 18, 2023
0
33
For patients with mild-to-moderate COVID-19, treatment with fluvoxamine does not improve time to sustained recovery versus placebo, according to a study published online Jan. 12 in Journal of the American Medical Association.
Jan 13, 2023
0
35
